Exelixis. has been granted a patent for crystalline forms of the c-Met inhibitor, Compound 1, including its hemifumarate salt. The invention encompasses pharmaceutical compositions and methods for treating diseases by modulating protein kinase activity. GlobalData’s report on Exelixis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Exelixis, Cancer treatment biomarkers was a key innovation area identified from patents. Exelixis's grant share as of June 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline forms of c-met inhibitor compound 1
The granted patent US12017995B2 introduces a crystalline hemifumarate salt of a specific compound, referred to as Compound 1. This salt form is characterized by its unique crystalline structure, which may enhance the stability and bioavailability of the compound in pharmaceutical applications. The patent claims the distinct properties of this hemifumarate salt, suggesting potential advantages over other forms of the compound, such as improved solubility or reduced side effects.
Additionally, the patent outlines a pharmaceutical composition that includes the crystalline hemifumarate salt of Compound 1 in combination with a pharmaceutically acceptable excipient. This composition is designed to facilitate the effective delivery of the active ingredient, ensuring that it meets regulatory standards for safety and efficacy. The inclusion of excipients is crucial for the formulation process, as they can influence the drug's release profile and overall performance in therapeutic settings.
To know more about GlobalData’s detailed insights on Exelixis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
